Cargando…
Autologous Stem Cell Transplantation for Myeloma: Cytoreduction or an Immunotherapy?
The incidence of multiple myeloma (MM), a bone marrow (BM) resident hematological malignancy, is increasing globally. The disease has substantial morbidity and mortality and remains largely incurable. Clinical studies show that autologous stem cell transplantation (ASCT) remains efficacious in eligi...
Autores principales: | Minnie, Simone A., Hill, Geoffrey R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7994609/ https://www.ncbi.nlm.nih.gov/pubmed/33777050 http://dx.doi.org/10.3389/fimmu.2021.651288 |
Ejemplares similares
-
Autologous Hematopoietic Stem Cells Are a Preferred Source to Generate Dendritic Cells for Immunotherapy in Multiple Myeloma Patients
por: Shinde, Prajakta, et al.
Publicado: (2019) -
Immunomodulatory Drugs in the Context of Autologous Hematopoietic Stem Cell Transplantation Associate With Reduced Pro-tumor T Cell Subsets in Multiple Myeloma
por: Di Lullo, Giulia, et al.
Publicado: (2019) -
Increased Immune-Regulatory Receptor Expression on Effector T Cells as Early Indicators of Relapse Following Autologous Stem Cell Transplantation for Multiple Myeloma
por: Lee, Lydia, et al.
Publicado: (2021) -
NK Cell Reconstitution After Autologous Hematopoietic Stem Cell Transplantation: Association Between NK Cell Maturation Stage and Outcome in Multiple Myeloma
por: Orrantia, Ane, et al.
Publicado: (2021) -
Autologous Hematopoietic Stem Cell Transplantation for Treatment of Systemic Sclerosis
por: Del Papa, Nicoletta, et al.
Publicado: (2018)